Based on ratings from 7 stock analysts, the Quidel Corp stock price is expected to increase by 28.39% in 12 months. This is calculated by using the average 12-month stock price forecast for Quidel Corp. The lowest target is $44 and the highest is $64. Please note analyst price targets are not guaranteed and could be missed completely.
About 7 Wall Street analysts have assignedQDEL 5 buy ratings, 2 hold ratings, and 0 sell ratings. This means that analysts expect Quidel Corp to buy. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on QDEL. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.
These are the latest 20 analyst ratings of QDEL.
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
---|---|---|---|---|
John Sourbeer UBS | Neutral | $50 | Upgrade | Sep 19, 2024 |
Alexander Nowak Craig-Hallum | Buy | $57 | Upgrade | Sep 5, 2024 |
Conor McNamara RBC Capital | Outperform | $61 | Reiterates | Aug 16, 2024 |
Conor McNamara RBC Capital | Outperform | $61 | Reiterates | Aug 1, 2024 |
Conor McNamara RBC Capital | Outperform | $68 | Maintains | May 9, 2024 |
John Sourbeer UBS | Sell | $42 | Downgrade | Mar 4, 2024 |
Andrew Brackmann William Blair | Market Perform | Downgrade | Feb 14, 2024 | |
Alexander Nowak Craig-Hallum | Hold | Downgrade | Feb 14, 2024 | |
Conor McNamara RBC Capital | Outperform | $81 | Maintains | Feb 14, 2024 |
Casey Woodring JP Morgan | Underweight | $37 | Downgrade | Feb 14, 2024 |
Andrew Cooper Raymond James | Outperform | $76 | Downgrade | Feb 14, 2024 |
Conor McNamara RBC Capital | Outperform | $130 | Maintains | Dec 21, 2023 |
Patrick Donnelly Citigroup | Neutral | $72 | Downgrade | Dec 11, 2023 |
Andrew Cooper Raymond James | Strong Buy | $100 | Maintains | Nov 2, 2023 |
Conor McNamara RBC Capital | Outperform | $140 | Reiterates | Sep 19, 2023 |
Raymond James | Strong Buy | Maintains | Aug 15, 2023 | |
JP Morgan | Neutral | Maintains | Aug 9, 2023 | |
RBC Capital | Outperform | Reiterates | Aug 9, 2023 | |
Conor McNamara RBC Capital | Outperform | $133 | Maintains | May 4, 2023 |
Andrew Cooper Raymond James | Strong Buy | $130 | Maintains | Feb 16, 2023 |
When did it IPO
1992
Staff Count
7,100
Country
United States
Sector/Industry
Healthcare/Medical Devices
CEO
Mr. Brian J. Blaser
Market Cap
$2.94B
In 2023, QDEL generated $3.00B in revenue, which was a decrease of -8.21% from the previous year. This can be seen as a signal that QDEL's business is declining, and its share price could be worth less in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Summary - The healthcare diagnostics specialist surpassed earnings expectations, achieving better-than-anticipated profits despite a minor decline in revenue.
Why It Matters - Exceeding earnings expectations amid a revenue drop indicates strong management and operational efficiency, potentially boosting investor confidence and stock performance.
Summary - QDEL's Q3 results show growth in non-respiratory revenues and reduced operating expenses year-over-year, but gross margins have declined.
Why It Matters - QDEL's growth in non-respiratory revenues and reduced operating expenses indicate operational efficiency, but declining gross margins may signal potential profitability concerns for investors.
Summary - QuidelOrtho Corporation (NASDAQ: QDEL) will hold its Q3 2024 earnings conference call on November 7, 2024, at 5:00 PM ET. Key executives will present financial results.
Why It Matters - QuidelOrtho's Q3 earnings call indicates financial performance insights, which can influence stock valuation and investor sentiment based on earnings results and future guidance.
Summary - QuidelOrtho Corporation reported solid financial results for Q3 2024, highlighting growth and margin improvement aligned with its strategic priorities.
Why It Matters - QuidelOrtho's solid Q3 results indicate effective strategic execution, suggesting potential growth and improved margins, which can positively impact stock performance and investor sentiment.
Summary - QuidelOrtho (QDEL) reported Q3 earnings of $0.85 per share, surpassing the Zacks Consensus Estimate of $0.31, but down from $0.90 per share a year earlier.
Why It Matters - QuidelOrtho's significant earnings beat signals strong performance and potential growth, despite a slight year-over-year decline, impacting investor sentiment and stock valuation.
Summary - Kuehn Law is investigating potential breaches of fiduciary duties by officers and directors of QuidelOrtho Corporation (NASDAQ: QDEL), which may impact shareholder interests.
Why It Matters - The investigation into QuidelOrtho's officers and directors for potential fiduciary breaches could lead to legal repercussions, affecting stock performance and shareholder value.